Skip to content

Illumina Is in Talks With EU to Divest Grail, Reuters Says

Illumina Inc. is in discussions with European Union authorities to divest Grail, as regulators seek to block the company’s $8 billion acquisition of the cancer-detection startup, Reuters reported.

EU regulators have opposed the deal between the San Diego-based DNA-sequencing giant and Grail over concerns the tie-up could give Illumina outsize ability to halt competitors from developing their own cancer screening tests.